Coloplast A/S Overview
Latest ROE for Coloplast A/S: 15.12% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow15.12%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Coloplast A/S's return on equity stands at 15.12%. That is above the Healthcare sector average of 11.15%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Coloplast A/S sits higher the Healthcare benchmark (11.15%) with a ROE of 15.12%. That is roughly 35.6% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 15.12% for Coloplast A/S means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Coloplast A/S's ROE evolved across reporting periods, while the comparison chart places CBHD.DE next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Coloplast A/S's reading of 15.12% (sector avg 11.15%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
